Autologous Serum Eye Drops for Post-Chemical Injuries and Corneal Epithelial Defects by Janicijevic-Petrovic, Mirjana A. et al.
  
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2013 Dec 15; 1(1):45-49.                                                                                                                                                                               45 
 
Open Access Macedonian Journal of Medical Sciences. 2013 Dec 15; 1(1):45-49. 
http://dx.doi.org/10.3889/oamjms.2013.009 
Clinical Science 
 
 
 
Autologous Serum Eye Drops for Post-Chemical Injuries and 
Corneal Epithelial Defects 
 
 
Mirjana A. Janicijevic-Petrovic
1
, Marko Petrovic
2
, Dragan Vujic
2
, Katarina Janicijevic
2
, Andrijana Popovic
2 
1
Clinic of Ophthalmology, Clinical Centre of Kragujevac, Kragujevac, Serbia; 
2
Faculty of Medical Sciences, University of 
Kragujevac, Kragujevac, Serbia 
 
 
 
Citation: Janicijevic-Petrovic MA, Petrovic M, 
Vujic D, Janicijevic K, Popovic A. Autologous 
Serum Eye Drops for Post-Chemical Injuries 
and Corneal Epithelial Defects. OA Maced J 
Med Sci. 2013 Dec 15; 1(1):45-49. 
http://dx.doi.org/10.3889/oamjms.2013.009 
Key words: autologous serum; eye drops; 
chemical injuries; corneal defects; treatment. 
*
Correspondence: Mirjana A. Janicijevic-
Petrovic. Clinic of Ophtalmology, Clinical Centre 
of Kragujevac, Zmaj Jovina 30, Kragujevac, 
Serbia. Mob: +38166013691. Fax: 
+38134370073. 
E-mail:mira.andreja@yahoo.com 
Received: 23-Aug-2013; Revised: 21-Sep-
2013; Accepted: 26-Oct-2013; Online first: 
30-Oct-2013 
Copyright: © 2013 Janicijevic-Petrovic MA. 
This is an open-access article distributed under 
the terms of the Creative Commons Attribution 
License, which permits unrestricted use, 
distribution, and reproduction in any medium, 
provided the original author and source are 
credited. 
Competing Interests: The authors have 
declared that no competing interests exist. 
 
 
 
 
 
 
Abstract  
Aim: To evaluate success rate (efficacy, safety) in treatment of post-chemical injuries and corneal 
defects using autologous serum eye drops.  
Material and Methods: Authors reviewed 93 patients (116 eyes) hospitalized in Clinic of 
ophthalmology from 2010 to 2013, who had post-causoma corneal defects that were nonresponsive 
to conventional treatment and were treated with serum therapy. Authors correlated time of 
epithelialization of defects with rate of epithelial healing. 
Results: Authors investigated 93 patients (52 males, 41 females; aged 18 - 74) for treatment of 
corneal defects. Application of autologous serum therapy 56 (48.28%) of 116 eyes was healed in 
an average time of 4 weeks. Among 116 eyes, epithelial defects healed in 4 (3.45%) within 1 week, 
in additional 17 (14.65%) in 1-2 weeks, totalling 31 (26.72%) within 3 weeks. Five eyes (4.31%) 
completely healed at 5 week; three eyes (2.59%) had subsequent healing of epithelial defect at 6 
week; 56 eyes completely healed within one month, and the remaining eight eyes healed within 1.5 
month. 
Conclusion: Using serum therapy, it was managed to reduce time of healing from eleven weeks, 
which were necessary just couple years ago (before 2010) to four (maximum six) weeks to 
complete healing which are necessary today.   
 
 
 
 
 
 
  
Introduction 
 Authors evaluate the efficacy and safety of 
autologous serum application in the treatment of post-
causoma large and persistent corneal epithelial 
defects (time of closure of serious epithelial defects). 
Authors have established the protocol for the use of 
autologous serum in the ophthalmic practice (eye drop 
form) and reported as the relative new serum 
treatment for serious chemical eye injuries (causoma).  
 Chemical eye injuries are described as urgent 
trauma of eye (an urgent ophthalmologic pathology) 
and localized mostly on anterior segment with 
complications and residual sequels as corneal 
persistent epithelial defects, macular corneal 
opacities, dry eye, etc. Diagnostic procedure is easy, 
but therapy is complex.  
 The serum therapy has the biomechanical and 
biochemical properties similar to normal human tears. 
Tear film components, such as growth factors, 
fibronectin and vitamin A play the most important role 
in the functional proliferation, migration and 
differentiation of corneal and conjunctiva epithelium 
(epitheliotrophic effect on the ocular surface). The 
autologous serum contains immunoglobulin such as 
IgG, lisozyme and supplemental factors, which endow 
it with certain bactericide and bacteriostatic effects. 
Serum exhibits characteristics which are similar to 
those of tears as regards the pH and the osmolarity. 
Like tears, it contains growth factors and bactericides 
which allow the treatment with topical autologous 
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serum not only to humidify the eye surface, but to 
provide nutritional and growth factors necessary to 
maintain cellular feasibility in the epithelial repair 
processes and which reduce the risk of 
contaminations. Varying methods for the preparation 
and regime to application of autologous serum eye 
drops were used as well as different concentrations 
[1].  
 
Material and Methods 
  Authors reviewed the medical records of the 116 
eyes from the 93 patients which hospitalization in the 
our Clinic of ophthalmology from the 1
st
 June 2010 to 
the 1
st
 June 2013, who had post-causoma persistent 
corneal epithelial defects that were nonresponsive to 
conventional topical medical treatment, and were 
treated with autologous serum eye drops.  Authors 
correlated the time duration of the epithelialization of 
defects due to usage of autologous serum eye drops 
with rate of epithelial healing. 
 Autologous serum was prepared from whole blood. 
Blood was obtained from the patients who were 
healthy and had no history of bacteremia, hepatitis, 
HIV, fungal infection, etc.  
 The patients applied the serum eye drops once 
every two hours for 30 and more days (50% diluted of 
autologous serum).   
 All patients underwent the complete clinical 
ophthalmic examination. Patients were examined 
before treatment and on weekly basis during the 
treatment. Clinical examination included clinical 
evolution with fluorescing staining pattern of the 
cornea, Schemer's tests (normal, 10 mm/5 minutes or 
more) and tear film break-up time (normal, 10 
seconds or more).  Large and unusual epithelial 
defects were measured with the slit beam. 
Fluorescing staining scores (Fl +++, Fl ++, Fl +, Fl +/-, 
Fl ø) as well as subjective symptom grading, were 
performed at hospitalization and weekly during the 
treatment.  
 In our study we extracted blood, which was 
distributed in tubes. Subsequently the tubes were left 
in vertical position at 22°C for about 2 hours to allow 
coagulation. Authors directly centrifuge the blood and 
waited up to two days. After coagulating the blood it 
was centrifuged to separate the autologous serum for 
10 minutes at 5000 rpm. The time and power of 
centrifugation is important in producing the amount of 
autologous serum without producing hemolysis and 
on the contrary, it is considered that with less 
centrifugal force or less time not only less serum is 
obtained but it can retain remains of platelet 
membranes which, if the dosage is large enough, can 
cause cell apoptosis. After separating the serum, 
authors go on to prepare the eye drops with fresh 
serum or store it in test tubes shielded from light by 
aluminum paper. Most prepared all the autologous 
serum eye drops with fresh serum, giving the flasks to 
the patient for their utilization, recommending them to 
keep the one in use in the refrigerator at 4ºC and 
storing the rest at –20°C. The utilization of 20% 
concentration of autologous serum is empirical, in fact 
no significant differences have been found between 
the migration of epithelial cells of in vitro cultures with 
concentration between 10% and 20%. Some authors 
believe that the greater concentration would have 
more effect on the eye surface. These authors utilize 
concentrations of 50% and 100%. The most 
standardized utilization of autologous serum is at 
concentration of 20% or 50%. This concentration 
seems sufficient and avoids the irritations derived 
from the higher viscosity of highly concentrated 
preparations, and considerably reduces the number of 
blood extractions. The number of applications varies 
from once every hour to three times a day (instillations 
every 2-3 hours and utilize the same flask for one 
week). Patients in this study used 50% autologous 
serum, one every 2-3 hours, during day and the same 
flask was used for seven days. Authors haven’t had 
any case of conjunctivitis or corneal infections due to 
the application of autologous serum eye drops. For 
patients in study the autologous serum was obtained 
from the Clinic for Transfusion.  
 The statistical analyzes done by SPSS program 
versus 19 (by the Chi-Square test; p values are 
calculated with significant level of 0.05).  
  
Results  
 A total of the 116 eyes from the 93 patients (51 
males and 42 females; aged between of min - 18 and 
max - 74) failed conventional topical medical therapy 
for treatment of the corneal epithelial defects and 
were treated with 50% autologous serum eye-drops to 
every 2 hours while awake.  
 The median time duration of the epithelial defects 
prior to initiation of autologous serum eye drops was 
4.63 weeks. After institution of autologous serum 
therapy, 56 of the 116 eyes healed in the mean time 
of 28.1 days. The 56 (48.28%) of eyes healed within 4 
weeks of starting therapy with 50% autologous serum 
eye drops. The number of days required for healing 
was associated with the length of time the defect was 
open prior to initiation of serum drops. 
 Among the 116 eyes, the epithelial defect healed 
in 4 (3.45%) within 1 week, in an additional 17 
(14.65%) in 1-2 weeks, the totaling 31 (26.72%) within 
3 weeks. Five eyes (4.31%) did completely heal at the 
5 week; 6 eyes (2.59%) had subsequent healing of 
the discrete epithelial defect at the 6 week; 56 eyes 
completely healed within one month, and the 
remaining 8 eyes healed within 1.5 month. The time 
period of autologous serum treatment ranged from 7 - 
42 (10+/-3 days).  
 Authors proved that there was no statistically 
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significant difference between the number of gender in 
our hospitalized patients with chemical injuries of the 
eyes (χ
2
=1.301, p=0.254) (Table 1). 
 
Table 1: Frequency of chemical eye injuries by age groups and 
gender. 
Age groups 
Gender 
∑ 
Male Female 
18-32 15 16 31 
33-46 17 13 30 
47-60 16 10 26 
61-74 4 2 6 
Total 52 41 93 
 
 Authors proved that there were no statistically 
significant differences between the age groups of 
patients and distribution of the time of complete 
epithelialization defect in the cornea by the number of 
weeks to during the healing process (χ
2
=22.334, p= 
0.099). We showed that the healing time was 
statistical significant and associated with young age 
groups (χ
2
=17.667, p=0.001) (Table 2).  
 
Table 2: Correlation between age groups and the length of 
healing. 
Age groups 
                      Number of weeks the length healing 
0 I II III IV V VI 
18-32  31 3 4 9 14 1 0 
33-46  30 4 4 9 12 0 1 
47-60  26 1 3 6 13 2 1 
61-74  6 0 0 3 0 2 1 
4 groups 93 8 11 27 39 5 3 
 
 We had also shown that the time of complete 
epithelialization defects of cornea lasted until 6 weeks 
(fl + / - as well as clinical signs of epithelialization) and 
was high statistical significant differences in the 
second, the third and the fourth week of 
hospitalization (number of the eyes) and in most of 
our patients (χ
2
=319.508, p<0.01) (Table 3). 
 
Table 3: The correlation between the size of defect and the 
length of healing. 
Clinical signs 
(size of defect) 
 Number of weeks length of healing 
  0 I II III IV V VI 
   Fl +++  107 90 49 1 0 0 0 
 Fl ++  5 5 15 7 3 0 0 
FL +  4 12 19 8 4 1 0 
 Fl +/-  0 5 12 48 4 2 0 
   Fl ø  0 4 17 31 56 5 3 
Total ayes 116 116 112 95 64 8 3 
 
 Clinical manifestations and slit-lamp exam of 
findings were in relation to the severity of the 
keratopathy. Many patients showed the subjective 
improvement of keratopathy symptoms after the 
autologous serum applications. None of the samples 
examined showed signs of bacterial or fungal infection 
or allergic irritation. There were no local side effects 
from autologous serum therapy.  
 The corneal epithelialization, corneal epithelial cell 
squamous metaplasia and tear stability improved 
significantly with the therapy, but the visual acuity, 
regression of vascular pannus and subepithelial 
scarring showed only slight improvement with this 
treatment.  
  
Discussion 
 Authors correlated the median time duration of the 
epithelialization of defects due to usage of autologous 
serum eye drops with rate of epithelial healing. Using 
autologous serum eye drops it was managed to 
reduce the time of healing from eleven weeks (2.5 
mounts), which were necessary just couple years ago 
(before 2010) to four (maximum six 1.5 mount) weeks 
to complete healing which are necessary today.  
 After the treatment there were no indications for 
surgical therapy such as penetrating keratoplasty, 
conjunctiva-plastic, amniotic membrane transplan-
tation, etc.     
  The clinical studies (personal experience and 
literature reviews) performed showed a variable 
efficacy with the preparative process and the use of 
autologous serum eye drops varying considerably 
between the different studies including this study, too 
[2].  
 The use of 50% autologous serum eye drops 
appears to be an efficacious treatment modality for 
persistent corneal epithelial defects that are 
recalcitrant to conventional therapy [3], what this study 
proved.  
 In patients for whom serum treatment is indicated, 
but autologous serum is unavailable or unsuitable for 
use, the allogeneic serum offers an alternative option 
for therapy [4], what was not the cases in this study.  
 Platelet-rich plasma harbors with high 
concentrations of growth factors related to the 
promotion of many types wound healing. It could be 
an effective treatment option for chronic ocular 
surface disease and other similar diseases as our 
post-causoma injures [5].  
 A clinical pilot study was carried out to examine 
potential uses and in vitro toxicity testing on corneal 
epithelial cell cultures was performed to compare the 
effect of serum drops with unpreserved hypromellose 
(hydroxypropylmethylcellulose). In vitro toxicity testing 
demonstrated that serum drops have reduced toxicity 
compared with unpreserved hypromellose [6], but 
patients in our study applied only autologous serum 
without use of hypromellose or similar products.  
 Autologous serum eye drops were found effective 
in the treatment of severe dry eye diseases and 
others corneal problems as evidenced by 
improvement of tear stability and ocular surface vital 
staining scores [7].  
 Some studies showed the effect of autologous 
serum eye drop application in the aniridic keratopathy.  
Autologous serum eye drops improved aniridic 
keratopathy in patients with light or moderate severity. 
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In these patients, use of autologous serum eye drops 
was superior to conventional therapy with substitute 
tears for improving the ocular surface and the 
subjective comfort [8].  
 Eye drops prepared from autologous serum are a 
relative new treatment option for severe ocular 
surface disease. It supports the migration of corneal 
epithelial cells and the differentiation of conjunctiva 
epithelial cells. Methodological variations determine 
the biochemical properties and thus the known 
epitheliotrophic effect of serum eye drops [1].  
 Effectiveness of serum treatment has been proven 
for many diseases: chemical eye injuries, 
keratoconjunctivitis sicca, superior limbic 
keratoconjunctivitis, recurrent erosion syndrome and 
persistent epithelial defects. A unified standard of 
preparing the autologous serum eye drops has not 
been elaborated and in various publications different 
modes of preparation of the solution have been used. 
It is important to document indications for this 
treatment appropriately, as well as to be cautious 
while preparing and using the solution [9].  
 Authors review showed the mechanisms 
responsible for maintenance of corneal homeostasis 
as well as the development the modes of treatment for 
various corneal diseases. The resident cells of the 
cornea-epithelial cells, fibroblasts and endothelial cells 
also engage in mutual interactions through the 
network systems. In seeking an alternative to 
fibronectin eye drops, authors were investigating the 
effects of a peptide corresponding to the second cell-
binding domain of fibronectin on corneal epithelial 
wound healing. Triptolide or its derivatives are thus 
potential drugs for the treatment of corneal ulcer and 
would work by acting directly on corneal fibroblasts 
rather than by inhibiting the secreted enzymes (matrix 
metalloproteinase) responsible for collagen 
degradation [10].  
 The other study of the impact of topical treatment 
with autologous serum on the clinical evolution of 
persistent corneal epithelial defects, observed its 
effect on the squamous metaplasia in cases of dry 
eye.  Autologous serum treatment accelerates healing 
and application causes an involution of squamous 
metaplasia [11].  
 Autologous serum was prepared from the patients, 
diluted to 20% and used six to ten times a day.  The 
concentration of vitamin A, epidermal growth factor 
and transforming growth factor-beta was measured at 
1 week and 1 month (stored in the refrigerator and 1 
month and 3 months in the freezer) [12], but we, 
serum used by patients in this study prepared and 
stored in a different way, it was obtained from the 
patients and diluted to 50% and patients were 
instructed to use is once every 2-3 hours, but it was 
stored in refrigerator on 4ºC for seven days.  
 Authors determine the efficacy of autologous 
serum drops in the treatment of superior limbic 
keratoconjunctivitis.  Autologous serum application 
can be used as an alternative mode of therapy in this 
and known corneal pathology [13].  
 Authors studied the effect of topical fibronectin on 
epithelial injures healing and ulceration in alkali-
burned the rabbit corneas. Fibronectin accelerated the 
complete surface re-epithelialization. A prominent 
fibronectin-fibrinogen matrix remained on the surface 
of fibronectin-treated corneas, presumably aiding 
surface re-epithelialization and decreasing corneal 
ulceration [14].  
 Clinical studies showed a variable efficacy of 
serum approach, but the parameters for the 
production of blood product varied significantly. 
Clotting time, centrifugation and diluents have the 
significant impact on the composition and 
epitheliotrophic effects of the serum [15].  
 Expose shoved the elaboration process: 
microbiological control and effectiveness of eyewash 
prepared with the patient's serum for the treatment of 
injure corneas of different etiology. The eyewashes 
got ready under sterile conditions, using the patient's 
serum diluted to 20% with physiologic solution in the 
treatment in serious cases of chemical injures, dry 
eye, corneal ulceration [16], whose experience we do 
not share.  
 Investigate the sterility of non-preserved 
autologous serum drops in hospitalized patients with 
persistent corneal epithelial defects was conducted 
using blood, chocolate, endow, and Sabouraud agar 
media, the sterility of autologous serum drops was 
assessed on the day before application and on the 4
th
 
and 7
th
 days. Patients had received topical autologous 
serum therapy and prophylactic antibiotic drops for at 
least 7 days. By additional application of prophylactic 
antibiotic drops, infections may be avoided even if 
refrigerated non-preserved autologous serum is used 
up to 7 days [17], what authors applied on patient in 
this study.  
 As a conclusion, the application of autologous 
serum eye drops has proven to be effective, 
practicable and safe therapy in patients with post-
causoma corneal persistent epithelial defects. Using 
serum therapy, it was managed to reduce the time of 
healing from eleven weeks, which were necessary just 
couple years ago (before 2010) to four (maximum six) 
weeks to complete healing which are necessary 
today.  
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